From 67% to 97%: That’s a big improvement

Point-of-sale edit upped % of Rx with <7 days supply

February 9, 2020

A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply

Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.

Short Acting Opioid Duration Edit Substantially Reduces Large Day Supply for Commercially Insured Opioid Naïve Members Compared to a Control Group without an Edit (Fall 2019)

Related news

Perspectives

April 24, 2024

Prime/MRx resident wins AMCP Foundation Best Poster Award

Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes

Perspectives

April 23, 2024

Expert Clinical Network Insights: April 2024

A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

Perspectives

April 23, 2024

April Fraud Focus – How to prioritize drug safety at home  

While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…